Atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) combination therapy is now a first-line regimen for advanced HCC and as a result, more patients with advanced HCC may be down-staged with ICIs and become eligible for transplants. This evidence concerns the gene VEGFA and hepatocellular carcinoma.